EUVIMEDEUVIMED entdecken
LeserbriefOpen Access

Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation

Arash Abdolmaleki iD, Sina Jafari Dargahlou, Hussein A Ghanimi

Advanced Pharmaceutical Bulletin · 19.05.2026 · 16 (1) · 6-7

DOI: 10.34172/apb.46533 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Advanced Pharmaceutical Bulletin, online erschienen am 10.05.2026. Verfasst von Arash Abdolmaleki und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, Faculty of Advanced Technologies, University of Mohaghegh Ardabili, Namin, Iran. Die Arbeit nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • Department of Biophysics, Faculty of Advanced Technologies, University of Mohaghegh Ardabili, Namin, Iran.
  • College of Nursing, University of Al-Ameed, Karbala, Iraq.
  • Department of Clinical Laboratories, College of Applied Medical Sciences, University of Kerbala, Karbala, Iraq.

ORCID-Profile: Arash Abdolmaleki

Zitieren

APA

Abdolmaleki, A., Jafari Dargahlou, S., & A Ghanimi, H. (2026). Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation. Advanced Pharmaceutical Bulletin, 16(1), 6-7. https://doi.org/10.34172/apb.46533

Vancouver

Abdolmaleki A, Jafari Dargahlou S, A Ghanimi H. Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation. Advanced Pharmaceutical Bulletin. 2026;16(1):6-7. doi:10.34172/apb.46533

BibTeX
@article{Abdolmaleki2026,
  author = {Abdolmaleki, Arash and Jafari Dargahlou, Sina and A Ghanimi, Hussein},
  title = {Immunogenicity as a Key Challenge in Tissue Engineering: Toward Clinical Translation},
  journal = {Advanced Pharmaceutical Bulletin},
  year = {2026},
  volume = {16},
  number = {1},
  pages = {6--7},
  doi = {10.34172/apb.46533}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche